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Abstract
We quantitatively evaluated total and individual renal function by technetium-99m mercap-
toacetyltriglycine (Tc-99m MAG3) renal scintigraphy before and after radiofrequency ablation
(RFA) of renal tumors. Eleven patients who underwent Tc-99m MAG3 renal scintigraphy 1 week
before and after RFA were evaluated (7 men and 4 women ; age range : 23-83 years ; mean age
: 60.6 years). Five patients had solitary kidneys, and five had normally or minimally functioning
contralateral kidneys. One patient had a renal cell carcinoma in the contralateral kidney. One
patient with a solitary kidney underwent RFA a second time for a residual tumor. In patients with
a solitary kidney, MAG3 clearance decreased after 5 of 6 RFAs, and in patients with a normally
functioning contralateral kidney, MAG3 clearance decreased after 4 of 5 RFAs, but no significant
differences were observed between before and after treatments. In addition to the total MAG3
clearance, the split MAG3 clearance was evaluated in patients with a normally functioning con-
tralateral kidney. MAG3 clearance decreased in 4 of 5 treated kidneys, while it adversely increased
in the contralateral kidneys after 4 of 5 RFAs. No significant differences, however, were observed
between before and after treatments. The results of our study revealed no significant differences
in sCr, BUN, CCr, or MAG3 clearance between pre- and post-RFA values. These results support
data regarding the functional impact and safety of renal RFA in published reports. We evaluated
total and individual renal function quantitatively using Tc-99m MAG3 renal scintigraphy before
and after treatment. This scintigraphy was very useful in assessing the effects of RFA on renal
function.
KEYWORDS: kidney, renal tumor, radiofrequency ablation, Tc-99m MAG3 renal scintigraphy,
individual renal function
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adiofrequency ablation (RFA) has been investi-
gated as an alternative, minimally invasive 
treatment for various tumors,  including liver,  bone, 
and lung tumors [1-3].  Recently, a number of exper-
imental studies have demonstrated the feasibility and 
safety of renal RFA [4-7].
 In contrast to partial nephrectomy,  the gold stan-
dard of nephron-sparing treatment,  RFA,  destroys 
the tumor and a reduced margin of local healthy tis-
sue ; it is therefore expected to be less invasive than 
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partial nephrectomy.  Although there have been a few 
reports of the eﬀ ects of RFA on renal function,  to 
our knowledge [4-8],  no studies have been per-
formed as yet to evaluate the eﬀ ects of RFA on indi-
vidual renal function by scintigraphy.  Consequently, 
we quantitated total and individual renal function by 
technetium-99m mercaptoacetyltriglycine (Tc-99m 
MAG3) renal scintigraphy before and after RFA.  In 
addition,  we measured serum creatinine (sCr),  blood 
urea nitrogen (BUN),  and 24 h urinary creatinine 
clearance (CCr) compared with the Tc-99m MAG3 
clearance.
Materials and Methods
　　Patient characteristics. This prospective 
study was undertaken between May 2002 and 
September 2003 with the approval of our institu-
tional ethics committee.  A written informed consent 
was obtained from all patients before the initiation of 
treatment.  A total of 17 patients with renal cell car-
cinoma underwent RFA.  Among them,  we evaluated 
renal function after 12 RFAs in 11 patients sub-
jected to Tc-99m MAG3 renal scintigraphy 1 week 
before and after RFA (7 men and 4 women ; age 
range : 23-83 years ; mean age : 60.6 years) (Table 1). 
The tumors size ranged from 7-37 mm in diameter. 
Diagnosis of renal cell carcinoma was conﬁ rmed by 
needle biopsy in 5 cases. In the remaining 6 patients, 
diagnosis was established based on CT or MRI show-
ing a renal mass that became signiﬁ cantly enhanced 
in the arterial phase.
　　Five patients had solitary kidneys,  and 5 had nor-
mally or minimally functioning contralateral kidneys. 
One patient had a renal cell carcinoma in the contra-
lateral kidney.  Two had multiple tumors that were 
treated simultaneously.  One patient with a solitary 
kidney underwent RFA a second time for a residual 
tumor.
　　Radiofrequency ablation technique. RFA 
was performed under CT guidance.  The patients‘ 
vital signs were continuously monitored throughout 
the procedure. RFA was performed under local anes-
thesia,  and conscious sedation was induced by intra-
venously infused fentanyl chloride.  The procedure 
was performed using a single internally cooled elec-
trode the size of a 17-gauge needle (Cool-tip, 
Radionics,  Burlington,  MA,  USA).  Once proper 
electrode positioning was conﬁ rmed,  we attached the 
electrode to a 500-kHz monopolar radiofrequency 
generator (Cosman Coagulator-1, Radionics).  Tissue 
impedance was continuously monitored using the cir-
cuitry incorporated in the generator.
　　At the end of each treatment, perfusion was 
stopped and the maximal temperature was recorded. 
If the temperature exceeded 60℃,  the electrode was 
withdrawn.  If the temperature did not exceed 60℃, 
RFA was repeated at the same site.
　　On the basis of the size and geometry of the 
lesion,  overlapping ablations were performed by 
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Table 1　　Patient characteristics
Treatment no. Sex Age (y)
Side of treated 
Kidney Contralateral kidney
Treated tumor 
(number)
Tumor size
(mm)
1 female 76 left post nephrectomy 1 35
2 male 71 right post nephrectomy 1 28
3 female 23 left post nephrectomy 3 20,19,16
4 male 42 right intact 1 27
5 male 71 right intact 1 28
6 male 60 right post nephrectomy 1 32
7 female 77 left post nephrectomy 1 37
8 male 63 left post nephrectomy 1 20
9 male 83 left intact 1 29
10 female 64 bilateral （bilateral RCC） 3 23,21,7
11 female 26 left intact 1 15
12 male 71 right intact 1 34
* Treatment no. 1 and no.7 are done in the same patient.
7 months after ﬁ rst RFA (no.1),  second RFA (no.7) was performed for a residual tumor.
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repositioning the needle to ablate the entire tumor. 
If possible, patients were subjected to unenhanced 
and contrast-enhanced CT immediately after RFA.
　　Tc-99m MAG3 renal scintigraphy. All the 
patients underwent Tc-99m MAG3 renal scintigraphy 
within 1 week before and after RFA.  To ensure ade-
quate hydration,  the patients were asked to drink 
200 ml of water 30 min before the test.
　　Thereafter,  a single-head gamma camera with a 
general purpose,  low-energy collimator (GCA 901A/
HG,  Toshiba,  Tokyo,  Japan) was set behind the 
patient,  who was lying in the supine position.  Each 
patient was administered 370 MBq of Tc-99m MAG3 
by intravenous bolus injection.  Sequential timed-
image data stored in a 128×128 matrix were 
recorded by computer : 60 frames,  2-sec images for 
the initial 2 min and 168 frames,  10-sec images for 
28 min.
　　Regions of interests (ROIs) were assigned for 
each kidney and a perirenal background region. 
Computerized time-activity curves were generated 
from the sequential image data.
　　The renal clearance of MAG3 was calculated 
based on the absolute renal uptake in each kidney 
according to an equation reported by Itoh et al.  [9]. 
This absolute renal clearance was normalized to a 
body surface area of 1.73 m2,  and we used this value 
as the MAG3 clearance in this study. 
　　sCr,  BUN,  and CCr were also measured before 
and 1 week after RFA.
　　Statistical analysis. A paired t-test was used to 
compare sCr,  BUN,  CCr,  and MAG3 clearance 
before and after treatment.  Diﬀ erences were consid-
ered statistically signiﬁ cant at p < 0.05.
Results
　　Although most patients showed no complications, 
2 had postoperative perirenal hematomas that 
resolved spontaneously.  There was no evidence of 
clinically signiﬁ cant injury to the urinary collecting 
system.  Immediately after RFA,  9 patients under-
went unenhanced and contrast-enhanced CT.  Only 1 
of the 13 ablated tumors showed contrast enhance-
ment after administration of the contrast agent.  The 
levels of sCr,  BUN,  CCr,  and MAG3 clearance 
before and after treatments are shown in Fig.  1-3. 
The mean sCr was 1.10 mg/dl before treatment and 
1.13 mg/dl after the procedure.
　　In patients with a solitary kidney,  sCr increased 
after 4 of 6 RFAs.  CCr decreased after 3 of 5 
RFAs,  although 1 patient accidentally failed to 
examine CCr.  MAG3 clearance decreased after 5 of 
6 RFAs,  but no signiﬁ cant diﬀ erences were observed 
between pre- and post-RFA values (Fig. 1).
　　In patients with a normally functioning contralat-
eral kidney,  sCr increased after 3 of 5 RFAs,  CCr 
decreased after 3 of 5 RFAs,  and MAG3 clearance 
decreased after 4 of 5 RFAs,  but no signiﬁ cant dif-
ferences were observed between the pre- and post-
RFA values (Fig. 2).  In 1 patient who underwent 
RFA for bilateral renal cell carcinoma,  changes in 
sCr,  BUN,  CCr,  and MAG3 clearance after RFA 
were minimal.
　　In addition to the total MAG3 clearance,  the split 
MAG3 clearance was evaluated in patients with a 
normally functioning contralateral kidney (Fig. 3).  In 
the treated kidneys,  MAG3 clearance decreased 
after 4 of 5 RFAs.  In contrast,  in the contralateral 
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Fig. 1　　Plot of sCr,CCr,BUN,MAG3 clearance before and after RFA in patients with a solitary kidney.
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kidneys,  MAG3 clearance adversely increased after 
4 of 5 RFAs.
　　Description of a case. An 83-year-old man with 
a history of chronic hepatitis was found to have a 
mass in the left kidney during a periodical ultrasound 
examination (Fig. 4).  Contrast-enhanced CT scan 
revealed a mass 29 mm in diameter in the left kidney. 
He refused surgical excision of the renal tumor,  and 
the decision was made to treat the tumor with RFA.
　　Pretreatment MAG3 clearance of the left and 
right kidneys were 102.4 ml/min and 103.9 ml/min, 
respectively.  After obtaining informed consent, 
CT-guided RFA was performed under conscious 
sedation.  For this procedure,  a single internally 
cooled electrode the size of a 17-gauge needle was 
used.  The patient presented no RFA-related compli-
cations.  There was no evidence of impairment of the 
urinary collecting system.
　　Three days after RFA,  Tc-99m MAG3 renal scin-
tigraphy was performed.  Posttreatment MAG3 clear-
ance of the left kidney decreased to 74.9 ml/min,  and 
MAG3 clearance of the right kidney adversely 
increased to 129.1 ml/min.
　　The contrast-enhanced CT scan obtained 3 months 
after RFA showed no evidence of tumor enhance-
ment.  The zone of ablation extending beyond the 
tumor was minimal.
Discussion
　　RFA for renal tumors is minimally invasive,  and 
good results have been reported [4-7].  As for com-
plications,  hematoma, hematuria,  and renal function 
impairment have been reported [4-7].  RFA for 
renal tumors that abut calyces increase the risk of 
injury to the collecting system.  The most frequent 
complication involving the collecting system is hema-
tuia [5].  In our series,  most patients followed an 
uneventful course ; however,  2 patients experienced 
postoperative perirenal hematomas that resolved 
spontaneously.  No patient experienced gross hematu-
ria.
　　As for the impact of RFA on renal function, 
Pavlovich et al.,  in a series of 21 patients subjected 
to a total of 24 percutaneous RFAs for small renal 
tumors,  found that the mean serum creatinine of the 
group had not changed 2 months after the procedure, 
and that no patient had had an increase in serum cre-
atinine greater than 0.1 mg/dl [4]. 
　　Gervais et al.  evaluated 34 patients who under-
went RFA for 42 renal tumors [5].  Four complica-
tions occurred during or after 54 patient visits to the 
radiology department for ablation.  One patient expe-
rienced gross hematuria,  and his creatinine levels 
88 Acta Med.  Okayama　Vol.  60,  No.  2Mukai et al.
treated kidney
0
50
100
150
200
250
pre RFA post RFA
sp
lit
 M
A
G
3 
cl
ea
ra
nc
e 
(m
l/
m
in
)
p =0.25
contralateral kidney
0
50
100
150
200
250
pre RFA post RFA
sp
lit
 M
A
G
3 
cl
ea
ra
nc
e 
(m
l/
m
in
)
p =0.33
Fig. 3　　Plot of split MAG3 clearance in treated and contralateral 
kidneys before and after RFA.
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Fig. 4　　83-year-old man with a tumor in the left kidney. 
A,  Contrast-enhanced CT scan before RFA showing an enhanced 
mass (arrows) 29 mm in diameter in the left kidney ; B,  Pre-RFA 
MAG3 clearance of the left kidney was 102.4 ml/min, MAG3 
clearance of the right kidney was 103.9 ml/min ; C,  CT scan 
obtained during ablation showing the electrode tip positioned 
within the tumor (arrows) ; D,  Post-RFA MAG3 clearance of the 
left kidney decreased to 74.9 ml/min and MAG3 clearance of the 
right kidney adversely increased to 129.1 ml/min ; E,  Contrast-
enhanced CT scan obtained 3 months after RFA showing no 
evidence of tumor enhancement (arrows).  Although the area of 
low attenuation beside the tumor (arrowhead) is suggestive of a 
small cortical infarction,  the zone of ablation extending beyond 
the tumor was minimal.
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did not return to baseline.  Another patient with a 
solitary kidney experienced gross hematuria obstruct-
ing the ureter and required hospital admission and 
treatment consisting of ureteral stenting.  This 
patient’s creatinine level returned to a baseline of 1.8 
ml/dl after an increase to 2.8 mg/dl.  A 3rd patient 
developed a perirenal hematoma after RFA.  This 
patient’s creatinine levels returned to a baseline of 
2.5 mg/dl after an increase to 3.5 mg/dl.  In another 
patient with a solitary kidney,  a proximal ureteral 
stricture occurred after RFA.  The patient’s creati-
nine levels returned to a baseline of 2.1 mg/dl after 
an increase to 3.9 mg/dl. 
　　Roy-Choudhury et al. performed 14 RFAs for 11 
lesions in 8 patients [6].  The mean serum creatinine 
level was 1 mg/dl before RFA and 1.1 mg/dl after 
the procedure.  Only in 1 patient did the creatinine 
levels increase steadily from 1.4 to 2.9 mg/dl.  This 
patient had bilateral multiple aggressive renal tumors 
and left nephrectomy and had undergone multiple 
RFAs on the contralateral kidney.
　　Baere et al.  treated 5 patients with a histologi-
cally proven renal cell carcinoma with RFA [7]. 
Creatinine was 1.07 to 1.41 mg/dl before treatment 
and remained unchanged after treatment in 3 patients. 
In the remaining 2 patients,  one of whom had a soli-
tary kidney,  creatinine increased from 1.39 and 1.4 
mg/dl before to 1.64 and 2.02 mg/dl after RFA, 
respectively.  Creatinine returned to baseline in all 
patients within 2 months of RFA.
　　Johnson et al. evaluated pre- and post-RFA serum 
creatinine and blood pressure in 25 patients followed 
up for at least 6 months [8].  Changes in mean serum 
creatinine were not statistically signiﬁ cant.  No 
patient experienced new-onset hypertension or a 
worsening of existing hypertension.
　　In our series,  no signiﬁ cant diﬀ erences were 
observed between pre- and post-RFA sCr, 
BUN,  CCr,  or MAG3 clearance. 
　　We used MAG3 scintigraphy to evaluate the 
eﬀ ects of RFA on renal function in patients with 
renal tumors.  Compared to I-131 ortho-iodohippuric 
acid (I-131 OIH),  the biological properties of Tc-99m 
MAG3 seem to be inferior,  but its physiological 
properties are superior for external imaging.  In 
addition,  Tc-99m MAG3 is available as a kit,  which 
facilitates its use in a clinical setting.  Image quality 
is higher with Tc-99m MAG3 than that with I-131 
OIH because Tc-99m is a suitable agent for nuclear 
medicine imaging.  Therefore,  MAG3 clearance is an 
excellent index of renal function.
　　There are 2 methods of quantifying renal func-
tion : the plasma-sampling method and the external-
counting method.  The plasma-sampling method is an 
accurate method for determining renal clearance. 
However,  this method is technically complicated and 
requires frequent plasma sampling.  The external-
counting method using a gamma camera is very simple 
and enables simultaneous evaluation of renal function. 
Itoh’s method is especially useful for evaluating indi-
vidual renal function in Japanese.  The MAG3 clear-
ance calculated according to Itoh’s method is propor-
tional to the OIH clearance [9].
　　Shirasaki et al. evaluated the function of the 
remaining kidney after nephrectomy for renal cell 
cancer by Tc-99m MAG3 renal scintigraphy [10]. 
However,  to our knowledge,  there have been no 
reports of the eﬀ ects of RFA on renal function,  as 
evaluated by Tc-99m MAG3 renal scintigraphy. 
Shirasaki et al.  evaluated 30 patients who underwent 
unilateral radical nephrectomy by Tc-99m MAG3 
renal scintigraphy.  All patients underwent 3 Tc-99m 
MAG3 scintigraphy studies.  The ﬁ rst study was per-
formed before nephrectomy,  the second 1 month 
after surgery,  and the third 1 year after surgery. 
The mean MAG3 clearance of the remaining kidney 
increased,  with the average percentage increase 
being 39.5ｵ 1 month after nephrectomy and 40.5ｵ 
1 year after.  They concluded that adaptive hyper-
function occurs soon after nephrectomy.
　　Anderson et al. have reported that the eﬀ ective 
renal plasma ﬂ ow of the remaining kidney increases 
by approximately 30ｵ as early as 1 week after uni-
lateral nephrectomy and remains at levels higher than 
prenephrectomy levels for more than 10 years [11].
　　In our study of patients with functioning contra-
lateral kidneys,  MAG3 clearance of the treated kid-
neys decreased after 4 of 5 RFAs.  In contrast,  in 
the contralateral kidneys,  MAG3 clearance increased 
after 4 of 5 RFAs.  A compensatory reaction similar 
to that reported by Shirasaki et al. [10] and 
Anderson et al.  [11] may have occurred in the con-
tralateral kidney.  However,  the contribution of func-
tional impairment in the treated kidney may not be 
enough to cause a compensatory reaction in the con-
tralateral kidney.
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　　Surgery remains the standard treatment for renal 
carcinoma.  Nephron-sparing surgery was initially 
used to preserve renal function in patients with a sin-
gle functioning kidney,  and its high success rate in 
this subset of patients indicates that it could be used 
to treat small unilateral tumors [12, 13].  For 
patients who are considered high-risk candidates for 
surgery,  percutaneous RFA represents another 
treatment option.
　　Comparisons between nephron-sparing surgery 
and RFA are important to deﬁ ning their role in the 
treatment of renal tumors.  Duque et al.  reviewed 64 
patients who underwent 66 partial nephrectomies 
[13].  The most common complication was an 
increased creatinine level (twice the baseline value), 
occurring in 10 (15.1ｵ) procedures.  3 (4.5ｵ) 
patients required either temporary (n=1) or perma-
nent (n=2) dialysis.  Our results are favorable com-
pared with this standard,  especially when one consid-
ers that most of the patients in our series were 
ineligible for nephrectomy or at an extremely high 
risk if subjected to anesthesia and surgery.
　　Regarding the functional impact of RFA,  a poten-
tial advantage compared with most cases of partial 
nephrectomy is that,  during RFA,  clamping of the 
renal pedicle is not necessary.  Theoretically,  this 
could reduce the risk of renal ischemia and perma-
nent functional loss. 
　　There are some limitations to this study.  We 
used the external counting method to calculate MAG3 
clearance,  though this method is less reliable than 
the plasma sampling method. Besides,  the number of 
patients with a normally functioning contralateral 
kidney was too small to draw a deﬁ nite conclusion.
　　We evaluated total and individual renal function 
quantitatively using Tc-99m MAG3 renal scintigra-
phy before and after treatment.  And this scintigra-
phy was very useful to assess the eﬀ ects of RFA on 
renal function.
　　Conclusion. The results of our study revealed 
no signiﬁ cant diﬀ erences in sCr,  BUN,  CCr,  or 
MAG3 clearance between pre- and post-RFA values. 
These results support data regarding the functional 
impact and safety of renal RFA in published reports. 
Excellent outcomes in preservation of renal function 
support the validity of RFA for renal tumors.
　　Although our ﬁ ndings support the safety of RFA 
regarding its functional impact,  only long-term clini-
cal follow-up will deﬁ ne its role as a minimally inva-
sive,  nephron-sparing modality for the treatment of 
selected renal tumors.  Periodic long-term monitoring 
of renal function is still recommended,  especially in 
patients with a solitary kidney.
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